Adult Acute Lymphoblastic Leukemia
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: closed (31 December 2022) | Viewed by 10492
Special Issue Editor
Interests: Acute leukemia; hematopoietic stem cell transplantation; myelodysplastic syndromes; targeted therapy.
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear colleagues:
Unlike childhood acute lymphoblastic leukemia (ALL), adult ALL has historically had a dismal prognosis, with limited treatment options and cure rates less than 40%. However, over the last several decades, major advances in our understanding of the disease pathophysiology and genomics have led to better disease stratification and prognostication, which have improved the patient outcome. The development of intensified chemotherapy protocols has substantially improved the outcome of younger adults, with the goal of recapitulating the success observed in the pediatric population. Nevertheless, the outcome of older adults and patients with relapsed or refractory ALL remain poor. More recently, the concept of measurable residual disease (MRD) has become a standard of care in stratifying patients and in guiding treatment decisions, and the development of new diagnostic platforms such as next-generation sequencing (NGS) has introduced significant advances in the sensitivity of MRD diagnostics. Concomitantly, the treatment of ALL has been revolutionized with the advent of tyrosine kinase inhibitors (TKIs) in Philadelphia chromosome-positive ALL, and is currently moving forward in B-cell lineage ALL with the development of monoclonal antibodies targeting CD20, antibody-drug conjugates targeting CD22, bispecific antibodies, and CD19 chimeric antigen receptor T-cell therapy. Over the coming years, these new immunotherapeutic agents should deeply change the therapeutic strategies for adult ALL patients.
This Special Issue dedicated to adult ALL will highlight the current state of the art in this disease, with future prospects for improving therapies, and will recall the constant progresses made over the past years in the disease pathophysiology thanks to the advances in molecular biology, and in its treatment, with the development of immunotherapy.
Dr. Xavier Thomas
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- acute lymphoblastic leukemia
- adult ALL
- molecular biology
- treatment
- immunotherapy
